Stents for use in the interventional treatment of vascular disorders and vascular surgery

US2024050247A1 · US · A1

Patent metadata
FieldValue
Publication numberUS-2024050247-A1
Application numberUS-202118267810-A
CountryUS
Kind codeA1
Filing dateDec 14, 2021
Priority dateDec 17, 2020
Publication dateFeb 15, 2024
Grant date

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

In the stent for use in the interventional treatment of vascular diseases and in vascular surgery, there is a tubular support structure formed with struts made of a first bioresorbable metallic material that are joined to one another at selective points. The surface of the struts is fully covered by a coating made with a second bioresorbable metallic material. The second metallic material has a lower dissolution rate in the implanted state under physiological conditions in the course of bioresorption, and has a more positive electrode potential compared to the first metallic material.

First claim

Opening claim text (preview).

1 - 16 . (canceled) 17 . A stent for use in the interventional treatment of vascular diseases and vascular surgery, in which a tubular support structure, which is formed of struts that are connected to one another at selective points and made of a first bioresorbable metallic material, is formed and a completely covering coating, which is produced with a second bioresorbable metallic material, is created on the surface of the struts, the second metallic material having a lower dissolution rate under physiological conditions when implanted during bioresorption and a more positive electrode potential compared to the first metallic material. 18 . The stent according to claim 17 , wherein the surface of the struts, which are made of the first bioresorbable metallic material, is partially or completely provided with a surface structuring, which is produced with elevations and depressions. 19 . The stent according to claim 18 , wherein the surface of the struts, which are made of the first bioresorbable metallic material, is increased with a surface structuring by a factor of 1.1 to 10 compared to an electropolished surface of the struts. 20 . The stent according to claim 17 , wherein the surface structuring is created periodically and/or using grooves, troughs or valleys and/or elevations, using rings and/or peaks. 21 . The stent according to claim 17 , wherein the first metallic material is tungsten, molybdenum, or a base alloy of one of these two metals, at least one metal contained in a molybdenum base alloy being selected from W, Re, Nb, Ta and Mn; or at least one metal contained in the tungsten base alloy being selected from Mo, Re, Nb, Ta and Mn. 22 . The stent according to claim 17 , wherein the first metallic material is made of a molybdenum base alloy which contains at least 50 at % Mo or a tungsten base alloy which contains at least 50 at % tungsten. 23 . The stent according to claim 22 , wherein a molybdenum alloy is produced with at least one alloying element which is selected from W, Ta, Nb, Re and Mn and comprises the alloying element(s) W, Ta and/or Nb in a content of greater than 0 at % to less than 50 at % and/or the alloying element Re in a content of greater than 0 at % to 42 at % and/or the alloying element Mn in a content of greater than 0 at % to 36 at %. 24 . The stent according to claim 22 , wherein a tungsten alloy is produced with at least one alloying element which is selected from Mo, Ta, Nb, Re and Mn and comprises the alloying element(s) Mo, Ta and/or Nb in a content of greater than 0 at % to less than 50 at % and/or the alloying element Re in a content of greater than 0 at % to 37 at % and/or the alloying element manganese in a content of greater than 0 at % to 20 at %. 25 . The stent according to claim 17 , wherein the second metallic material is made of rhenium or a base alloy of rhenium, molybdenum or tungsten, at least one metal contained in the rhenium base alloy being selected from W and Mo or the metal contained in a molybdenum or tungsten base alloy being Re. 26 . The stent according to claim 25 , wherein a rhenium base alloy having a content of greater than 0 at % to 14 at % of Mo or a content of greater than 0 at % to 20 at % of W is produced. 27 . The stent according to claim 26 , wherein a molybdenum base alloy having a Re content of greater than 0 at % to 42 at % is produced, the content of Re being greater than the Re content in the first metallic material when this first material ( 4 ) is a MoRe alloy. 28 . The stent according to claim 26 , wherein a tungsten base alloy having a Re content of greater than 0 at % to 37 at % is produced, the content of Re being greater than the Re content in the first metallic material when this first material ( 4 ) is a WRe alloy. 29 . The stent according to claim 17 , wherein the second metallic material is pure molybdenum, if the first metallic material is produced with tungsten or with a tungsten base alloy which contains Mo, Ta, Nb and/or Mn. 30 . The stent according to claim 17 , wherein the sum of the volume of the second metallic material is less than the volume of the first metallic material ( 4 ) that is used to produce the stent struts. 31 . The stent according to claim 17 , wherein the coating is created with a layer thickness in the range of 1 nm to 1000 nm taking into consideration the dissolution rate and the time required for the restoration of the vessel wall. 32 . The stent according to claim 17 , wherein the coating is created with a layer thickness in the range of 1 nm to 50 nm taking into consideration the dissolution rate and the time required for the restoration of the vessel wall. 33 . The stent according to claim 17 , wherein the layer thickness of the coating on the surface of the struts varies.

Assignees

Inventors

Classifications

  • A61F2/91Primary

    made from perforated sheets or tubes, e.g. perforated by laser cuts or etched holes · CPC title

  • A61L31/022Primary

    Metals or alloys · CPC title

  • Materials at least partially resorbable by the body · CPC title

  • Other specific inorganic materials not covered by A61L31/084 or A61L31/086 · CPC title

  • Materials characterised by their function or physical properties {, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials} · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US2024050247A1 cover?
In the stent for use in the interventional treatment of vascular diseases and in vascular surgery, there is a tubular support structure formed with struts made of a first bioresorbable metallic material that are joined to one another at selective points. The surface of the struts is fully covered by a coating made with a second bioresorbable metallic material. The second metallic material has a…
Who is the assignee on this patent?
Fraunhofer Ges Forschung
What technology area does this patent fall under?
Primary CPC classification A61F2/91. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Thu Feb 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).